Showing 1 - 14 results of 14 for search '"Intravenous therapy"', query time: 0.05s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Pharmaceutical, Pharmacokinetic and Other Considerations for Intravenous to Oral Stepdown Therapy by Peter J Jewesson

    Published 1995-01-01
    “…Parenteral to oral stepdown therapy represents an effective cost containment strategy which can minimize intravenous therapy associated morbidity and may facilitate earlier hospital discharge. …”
    Get full text
    Article
  6. 6

    Outpatient Intravenous Antibiotic Therapy: The Vancouver Hospital experience by Grant Stiver, Amy Wai, Lynne Chase, Luciana Frighetto, Carlo Marra, Peter Jewessen

    Published 2000-01-01
    “…One hundred and ninety were accepted, 107 of whom were cared for under the VHHSC program and 83 of whom were discharged to continue intravenous therapy in their own health region. Thirty-four of 144 patients not accepted for outpatient intravenous therapy, were screened by the Infectious Disease Service and Pharmacy, and were discharged on oral antibiotics. …”
    Get full text
    Article
  7. 7

    Surgical Management of an Aspergillus Empyema in a 3-Year-Old Child by Meletios A. Kanakis, Konstantinos Th. Petsios, Nicholas M. Giannopoulos, Dimitrios Bobos, Sofia Hatzianastasiou, Lida C. Sianidou, Achilleas Lioulias

    Published 2020-01-01
    “…After surgical intervention and the diagnosis of invasive aspergillosis, intravenous therapy with voriconazole was initiated. During postoperative care, the patient’s condition remained stable with mild functional respiratory deficits. …”
    Get full text
    Article
  8. 8

    Mitoxantrone Therapy for Acute Posterior Multifocal Placoid Pigment Epitheliopathy with Cerebral Vasculitis by Hélène Massé, Jean-Laurent Guyomard, Dominique Baudet, Jean-François Pinel, Gilles Edan, Jean-François Charlin

    Published 2009-01-01
    “…A relapse of APMPPE was diagnosed, complicated with lymphocytic meningitis and cerebral ischemia. Intravenous therapy with mitoxantrone was performed in combination with methylprednisolone. …”
    Get full text
    Article
  9. 9

    Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy by Balázs Szalay, Gergő Mészáros, Áron Cseh, Lilla Ács, Magdolna Deák, László Kovács, Barna Vásárhelyi, Attila Balog

    Published 2012-01-01
    “…Measurements were done in 13 AS patients before and during the intravenous therapy with anti-TNF agent infliximab (IFX). …”
    Get full text
    Article
  10. 10

    Implementation and evaluation of a complex outpatient oral antimicrobial therapy program (COpAT) in Canada by Maggie Wong, Davie Wong

    Published 2025-01-01
    “…Compared to outpatient intravenous therapy, the total cost savings from COpAT were estimated to be $255,000 Canadian dollars (CAD), which translated to an average cost savings of $2500 CAD per patient per year. …”
    Get full text
    Article
  11. 11

    A decade-long overview of adverse events in a tertiary surgical service in South Africa by H Wain, D L Clarke, S Wall

    Published 2024-10-01
    “…Of those, adverse events related to indwelling devices (32.4%), iatrogenic injuries (12.5%) and intravenous therapy administration (12.5%) contributed most. …”
    Get full text
    Article
  12. 12

    Variability and performance of NHS England’s ‘reason to reside’ criteria in predicting hospital discharge in acute hospitals in England: a retrospective, observational cohort study... by Elizabeth Sapey, Simon Ball, David McNulty, Felicity Evison, Suzy Gallier, Katherine Reeves

    Published 2022-12-01
    “…In those remaining in hospital without eR2R, 61.2% met eR2R criteria on subsequent days (76% within 24 hours), most commonly due to increased NEWS2 (21.9%) or intravenous therapy administration (32.8%).Conclusions Reported R2R metrics are highly variable between and within acute Trusts in England. …”
    Get full text
    Article
  13. 13

    Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, Kristian Taipale, Dafne C A Quixabeira, Jorma Sormunen, Katriina Peltola, Suvi Sorsa, Santeri A Pakola, Elise Jirovec, Lyna Haybout, Claudia Kistler, Tatiana V Kudling, Victor Arias, James H A Clubb, Mirte van der Heijden, Teijo Pellinen, Joao M Santos

    Published 2025-01-01
    “…Transcriptional differences were seen in tumors after intravenous therapy and intratumoral therapy, with patients benefitting therapy showing stronger downregulation of immune activation at all time points.Conclusions TILT-123 therapy induced accumulation of effector lymphocytes in tumors. …”
    Get full text
    Article
  14. 14

    Mapping existing research on flushing peripheral vascular catheters: a scoping review protocol by Liping Liu, Peter J Carr, Orlaith Hernon, Jiaxin Deng, Catriona Duggan, Leo R Quinlan, Zina Alfahl

    Published 2025-01-01
    “…Introduction The peripheral vascular catheter (PVC) is the most common intravenous medical device used in hospitals, given it is crucial for the delivery of intravenous therapies. Despite its widespread use, PVC complications such as occlusion, infiltration, extravasation, phlebitis, thrombophlebitis, catheter-related thrombosis and catheter-related bloodstream infection significantly affect patient safety, leading to increased morbidity and healthcare costs. …”
    Get full text
    Article